{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:46:33Z","timestamp":1790952393046,"version":"4.1.0"},"reference-count":128,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.semnephrol.2019.10.009","type":"journal-article","created":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T18:48:42Z","timestamp":1576003722000},"page":"599-612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Hypoxia and Endothelial Dysfunction in Autosomal-Dominant Polycystic Kidney Disease"],"prefix":"10.1016","volume":"39","author":[{"given":"Marieta","family":"Theodorakopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Raptis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Loutradis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Sarafidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2019.10.009_bib0001","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1681\/ASN.2018050493","article-title":"Prevalence estimates of polycystic kidney and liver disease by population sequencing","volume":"29","author":"Lanktree","year":"2018","journal-title":"J Am Soc Nephrol."},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0002","first-page":"1356","article-title":"Prevalence of autosomal dominant polycystic kidney disease in the European Union","volume":"32","author":"Willey","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0003","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1097\/01.ASN.0000028643.17901.42","article-title":"Genetics and pathogenesis of polycystic kidney disease","volume":"13","author":"Igarashi","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0004","series-title":"Comprehensive clinical nephrology","first-page":"529","article-title":"Chapter 44: autosomal dominant polycystic kidney disease","author":"Torres","year":"2010"},{"issue":"Suppl 4","key":"10.1016\/j.semnephrol.2019.10.009_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival\u2013an analysis of data from the ERA-EDTA Registry","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0006","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2215\/CJN.01581105","article-title":"Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years","volume":"1","author":"Dicks","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0007","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1053\/j.ajkd.2014.05.020","article-title":"ESRD from autosomal dominant polycystic kidney disease in the United States, 2001-2010","volume":"64","author":"Reule","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0008","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2215\/CJN.09500911","article-title":"Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease","volume":"7","author":"Chapman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0009","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2174\/1573402111309010006","article-title":"Endothelial dysfunction and angiogenesis in autosomal dominant polycystic kidney disease","volume":"9","author":"Fick-Brosnahan","year":"2013","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0010","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1681\/ASN.V5122048","article-title":"Causes of death in autosomal dominant polycystic kidney disease","volume":"5","author":"Fick","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0011","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.ackd.2010.01.001","article-title":"Hypertension in autosomal dominant polycystic kidney disease","volume":"17","author":"Chapman","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0012","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nrneph.2009.13","article-title":"Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease","volume":"5","author":"Ecder","year":"2009","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0013","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/ckj\/sft031","article-title":"Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)","volume":"6","author":"Sans-Atxer","year":"2013","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0014","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Cornec-Le Gall","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0015","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0016","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0017","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0018","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1681\/ASN.V271219","article-title":"Cyst decompression surgery for autosomal dominant polycystic kidney disease","volume":"2","author":"Elzinga","year":"1992","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0019","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/MAJ.0b013e318256754f","article-title":"Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials","volume":"344","author":"He","year":"2012","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.transproceed.2013.10.040","article-title":"Sirolimus for treatment of autosomal-dominant polycystic kidney disease: a meta-analysis of randomized controlled trials","volume":"46","author":"Liu","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0021","doi-asserted-by":"crossref","first-page":"H33","DOI":"10.1152\/ajpheart.01102.2011","article-title":"Pkd2 mesenteric vessels exhibit a primary defect in endothelium-dependent vasodilatation restored by rosiglitazone","volume":"304","author":"Brookes","year":"2013","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0022","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/jch.12277","article-title":"Renal sympathetic-nerve ablation for uncontrolled hypertension in a patient with single-kidney autosomal dominant polycystic kidney disease","volume":"16","author":"Riccio","year":"2014","journal-title":"J Clin Hypertens Greenwich"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1573402111309010007","article-title":"The genetics of vascular complications in autosomal dominant polycystic kidney disease (ADPKD)","volume":"9","author":"Rossetti","year":"2013","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0024","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.ajhg.2016.05.004","article-title":"Mutations in GANAB, encoding the glucosidase II\u03b1 subunit, cause autosomal-dominant polycystic kidney and liver disease","volume":"98","author":"Porath","year":"2016","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0025","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1681\/ASN.2016090938","article-title":"Polycystic kidney disease without an apparent family history","volume":"28","author":"Iliuta","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0026","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3389\/fped.2017.00279","article-title":"The genetic and cellular basis of autosomal dominant polycystic kidney disease-a primer for clinicians","volume":"5","author":"Cordido","year":"2017","journal-title":"Front Pediatr"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0027","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ajhg.2018.03.013","article-title":"Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease","volume":"102","author":"Cornec-Le Gall","year":"2018","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0028","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ncpneph0070","article-title":"Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases","volume":"2","author":"Torres","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0029","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0030","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1091\/mbc.e07-02-0142","article-title":"Polycystin-1 induces cell migration by regulating phosphatidylinositol 3-kinase-dependent cytoskeletal rearrangements and GSK3beta-dependent cell cell mechanical adhesion","volume":"18","author":"Boca","year":"2007","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0031","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","article-title":"PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein","volume":"272","author":"Mochizuki","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0032","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCRESAHA.108.192765","article-title":"Ciliary polycystin-2 is a mechanosensitive calcium channel involved in nitric oxide signaling cascades","volume":"104","author":"AbouAlaiwi","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1681\/ASN.V1211","article-title":"Vascular expression of polycystin-2","volume":"12","author":"Torres","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0034","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1681\/ASN.V84616","article-title":"Vascular expression of polycystin","volume":"8","author":"Griffin","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/(SICI)1096-9896(199908)188:4<439::AID-PATH367>3.0.CO;2-P","article-title":"Cellular localization and tissue distribution of polycystin-1","volume":"188","author":"Peters","year":"1999","journal-title":"J Pathol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0036","doi-asserted-by":"crossref","first-page":"12174","DOI":"10.1073\/pnas.211191098","article-title":"Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene","volume":"98","author":"Boulter","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0037","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1073\/pnas.040550097","article-title":"Polycystin 1 is required for the structural integrity of blood vessels","volume":"97","author":"Kim","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0038","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0002-9440(10)65428-4","article-title":"Coordinate expression of the autosomal dominant polycystic kidney disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue","volume":"154","author":"Ong","year":"1999","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0039","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1590\/S0100-879X2011007500068","article-title":"Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease","volume":"44","author":"Bastos","year":"2011","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0040","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1172\/JCI64313","article-title":"Functional polycystin-1 dosage governs autosomal dominant polycystic kidney disease severity","volume":"122","author":"Hopp","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0041","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1093\/hmg\/ddh336","article-title":"Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease","volume":"13","author":"Lantinga-van Leeuwen","year":"2004","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0042","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1681\/ASN.2014121192","article-title":"The future of polycystic kidney disease research\u2013as seen by the 12 Kaplan awardees","volume":"26","author":"Antignac","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0043","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/ki.2015.207","article-title":"A polycystin-centric view of cyst formation and disease: the polycystins revisited","volume":"88","author":"Ong","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0044","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1093\/hmg\/ddp147","article-title":"Renal injury is a third hit promoting rapid development of adult polycystic kidney disease","volume":"18","author":"Takakura","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0045","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1093\/hmg\/ddp190","article-title":"Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways","volume":"18","author":"Happ\u00e9","year":"2009","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0046","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1681\/ASN.2013080864","article-title":"Scattered Deletion of PKD1 in kidneys causes a cystic snowball effect and recapitulates polycystic kidney disease","volume":"26","author":"Leonhard","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0047","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1681\/ASN.2007060688","article-title":"Vasopressin directly regulates cyst growth in polycystic kidney disease","volume":"19","author":"Wang","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0048","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2369-14-34","article-title":"Intracellular calcium release modulates polycystin-2 trafficking","volume":"14","author":"Miyakawa","year":"2013","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0049","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1016\/j.bbadis.2011.01.011","article-title":"Fluid transport and cystogenesis in autosomal dominant polycystic kidney disease","volume":"1812","author":"Terryn","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0050","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1083\/jcb.201006173","article-title":"The cell biology of polycystic kidney disease","volume":"191","author":"Chapin","year":"2010","journal-title":"J Cell Biol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0051","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/ki.2009.438","article-title":"Cyclic nucleotide signaling in polycystic kidney disease","volume":"77","author":"Wang","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0052","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000025693","article-title":"Contractility and endothelium-dependent relaxation of resistance vessels in polycystic kidney disease rats","volume":"36","author":"Wang","year":"1999","journal-title":"J Vasc Res"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0053","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0463.2004.apm1120606.x","article-title":"The expression and activity of renal nitric oxide synthase and circulating nitric oxide in polycystic kidney disease rats","volume":"112","author":"Wang","year":"2004","journal-title":"APMIS"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0054","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1046\/j.1523-1755.2003.00913.x","article-title":"Endothelial-derived vasoactive mediators in polycystic kidney disease","volume":"63","author":"Al-Nimri","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0055","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0272-6386(00)70265-4","article-title":"Gender-dependent effect of L-NAME on polycystic kidney disease in Han:SPRD rats","volume":"35","author":"Yoshida","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0056","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/path.2769","article-title":"Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-\u03b21 synthesis","volume":"223","author":"Mihout","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0057","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.lfs.2009.03.018","article-title":"Involvement of asymmetric dimethylarginine (ADMA) in glomerular capillary loss and sclerosis in a rat model of chronic kidney disease (CKD)","volume":"84","author":"Ueda","year":"2009","journal-title":"Life Sci"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0058","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1681\/ASN.V1181371","article-title":"Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease","volume":"11","author":"Wang","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0059","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1046\/j.1523-1755.2003.00236.x","article-title":"Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease","volume":"64","author":"Wang","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0060","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1053\/j.ajkd.2004.01.011","article-title":"Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease","volume":"43","author":"Kocaman","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0061","doi-asserted-by":"crossref","first-page":"986","DOI":"10.2215\/CJN.02330607","article-title":"Coronary flow velocity reserve and carotid intima media thickness in patients with autosomal dominant polycystic kidney disease: from impaired tubules to impaired carotid and coronary arteries","volume":"3","author":"Turkmen","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0062","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000101369","article-title":"Pulse wave reflection is amplified in normotensive patients with autosomal-dominant polycystic kidney disease and normal renal function","volume":"27","author":"Borresen","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0063","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1093\/ndt\/gfq806","article-title":"Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease","volume":"26","author":"Heffernan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0064","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2215\/CJN.05850518","article-title":"Vascular dysfunction, oxidative stress, and inflammation in autosomal dominant polycystic kidney disease","volume":"13","author":"Nowak","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0065","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ki.2014.241","article-title":"Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular nitric oxide release in humans","volume":"87","author":"Lorthioir","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0066","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ndt\/gfw013","article-title":"Vascular dysfunction in children and young adults with autosomal dominant polycystic kidney disease","volume":"32","author":"Nowak","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0067","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/ndt\/gfg351","article-title":"Autosomal dominant polycystic kidney disease: modifier genes and endothelial dysfunction","volume":"18","author":"Devuyst","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0068","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/hmg\/11.3.229","article-title":"Modifier effect of ENOS in autosomal dominant polycystic kidney disease","volume":"11","author":"Persu","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0069","doi-asserted-by":"crossref","first-page":"c101","DOI":"10.1159\/000157623","article-title":"Modifier effect of the Glu298Asp polymorphism of endothelial nitric oxide synthase gene in autosomal-dominant polycystic kidney disease","volume":"110","author":"Stefanakis","year":"2008","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0070","first-page":"69","article-title":"Role of endothelial nitric oxide synthase VNTR (intron 4 a\/b) polymorphism on the progression of renal disease in autosomal dominant polycystic kidney disease","volume":"3","author":"Elumalai","year":"2014","journal-title":"J Ren Inj Prev"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0071","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nephro.2007.02.002","article-title":"The past, presence and future of ADMA in nephrology","volume":"3","author":"Kielstein","year":"2007","journal-title":"Nephrol Ther"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0072","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1681\/ASN.V131170","article-title":"Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease","volume":"13","author":"Kielstein","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0073","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.ajkd.2007.09.020","article-title":"Asymmetric dimethylarginine and lipid peroxidation products in early autosomal dominant polycystic kidney disease","volume":"51","author":"Wang","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0074","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000353730","article-title":"Serum uric acid levels and endothelial dysfunction in patients with autosomal dominant polycystic kidney disease","volume":"123","author":"Kocyigit","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0075","doi-asserted-by":"crossref","first-page":"F1198","DOI":"10.1152\/ajprenal.00327.2014","article-title":"Endothelial dysfunction and oxidative stress in polycystic kidney disease","volume":"307","author":"Klawitter","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0076","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000355756","article-title":"Elevated asymmetric dimethylarginine is associated with oxidant stress aggravation in patients with early stage autosomal dominant polycystic kidney disease","volume":"38","author":"Raptis","year":"2013","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0077","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1093\/ndt\/gfh242","article-title":"Sympathetic hyperactivity in chronic kidney disease","volume":"19","author":"Blankestijn","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0078","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.bbadis.2011.06.012","article-title":"Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD)","volume":"1812","author":"Norman","year":"2011","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0079","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0300-483X(03)00129-X","article-title":"The nitric oxide donor, V-PYRRO\/NO, protects against acetaminophen-induced nephrotoxicity in mice","volume":"189","author":"Li","year":"2003","journal-title":"Toxicology"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1440-1797.2012.01659.x","article-title":"Role of asymmetrical dimethylarginine in the progression of renal disease","volume":"18","author":"Raptis","year":"2013","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0081","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2215\/CJN.04140510","article-title":"Inflammation, oxidative stress, and insulin resistance in polycystic kidney disease","volume":"6","author":"Menon","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0082","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1681\/ASN.V134991","article-title":"Oxidant stress and reduced antioxidant enzyme protection in polycystic kidney disease","volume":"13","author":"Maser","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0083","doi-asserted-by":"crossref","first-page":"R913","DOI":"10.1152\/ajpregu.00250.2005","article-title":"Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension?","volume":"289","author":"Wilcox","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0084","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2215\/CJN.08350813","article-title":"Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease","volume":"9","author":"Cadnapaphornchai","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0085","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3109\/00365590903359908","article-title":"Effect of pravastatin on kidney function and urinary protein excretion in autosomal dominant polycystic kidney disease","volume":"44","author":"Fassett","year":"2010","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0086","first-page":"109","article-title":"Effect of statin therapy on the progression of autosomal dominant polycystic kidney disease. A secondary analysis of the HALT PKD trials","volume":"13","author":"Brosnahan","year":"2017","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0087","doi-asserted-by":"crossref","first-page":"R1207","DOI":"10.1152\/ajpregu.00202.2014","article-title":"Determinants of renal tissue hypoxia in a rat model of polycystic kidney disease","volume":"307","author":"Ow","year":"2014","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0088","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000183332","article-title":"Serum immunoreactive erythropoietin levels in patients with polycystic kidney disease as compared with other hemodialysis patients","volume":"39","author":"Chandra","year":"1985","journal-title":"Nephron"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0089","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1056\/NEJMra1011165","article-title":"Oxygen sensing, homeostasis, and disease","volume":"365","author":"Semenza","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0090","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2353\/ajpath.2007.060455","article-title":"Involvement of hypoxia-inducible transcription factors in polycystic kidney disease","volume":"170","author":"Bernhardt","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0091","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1159\/000488115","article-title":"Levels of endocan, angiopoietin-2, and hypoxia-inducible factor-1a in patients with autosomal dominant polycystic kidney disease and different levels of renal function","volume":"47","author":"Raptis","year":"2018","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0092","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1681\/ASN.2013030209","article-title":"Hypoxia-inducible factor-1\u03b1 causes renal cyst expansion through calcium-activated chloride secretion","volume":"25","author":"Buchholz","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0093","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.kint.2018.06.008","article-title":"HIF-1\u03b1 promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease","volume":"94","author":"Kraus","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0094","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1523-1755.2001.00768.x","article-title":"Angiogenesis in autosomal-dominant polycystic kidney disease","volume":"60","author":"Bello-Reuss","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0095","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1038\/sj.ki.5001725","article-title":"Evidence of angiogenesis and microvascular regression in autosomal-dominant polycystic kidney disease kidneys: a corrosion cast study","volume":"70","author":"Wei","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0096","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/ki.2010.355","article-title":"Angiogenic growth factors correlate with disease severity in young patients with autosomal dominant polycystic kidney disease","volume":"79","author":"Reed","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0097","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/sj.ki.5002550","article-title":"VEGF receptor inhibition slows the progression of polycystic kidney disease","volume":"72","author":"Tao","year":"2007","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0098","doi-asserted-by":"crossref","first-page":"F773","DOI":"10.1152\/ajprenal.00058.2011","article-title":"Anti-VEGF antibody treatment accelerates polycystic kidney disease","volume":"301","author":"Raina","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0099","doi-asserted-by":"crossref","first-page":"18827","DOI":"10.1074\/jbc.272.30.18827","article-title":"Characterization of Fas (Apo-1, CD95)-Fas ligand interaction","volume":"272","author":"Schneider","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0100","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1159\/000345352","article-title":"Mononuclear leukocyte apoptosis and inflammatory markers in patients with chronic kidney disease","volume":"36","author":"Dounousi","year":"2012","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0101","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1093\/ndt\/gfq159","article-title":"Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway","volume":"25","author":"Yilmaz","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0102","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1159\/000489911","article-title":"Serum Fas ligand, serum myostatin and urine TGF-\u03b21 are elevated in autosomal dominant polycystic kidney disease patients with impaired and preserved renal function","volume":"43","author":"Raptis","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0103","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1007\/s11095-007-9515-x","article-title":"Cell-specific delivery of a transforming growth factor-beta type I receptor kinase inhibitor to proximal tubular cells for the treatment of renal fibrosis","volume":"25","author":"Prakash","year":"2008","journal-title":"Pharm Res"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0104","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1161\/01.HYP.27.5.1165","article-title":"Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade","volume":"27","author":"Yamada","year":"1996","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2215\/CJN.00910306","article-title":"Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease","volume":"2","author":"Torres","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0106","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/CIRCULATIONAHA.107.710111","article-title":"Endothelial cilia are fluid shear sensors that regulate calcium signaling and nitric oxide production through polycystin-1","volume":"117","author":"Nauli","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0107","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1093\/ndt\/gfy023","article-title":"Renal injury progression in autosomal dominant polycystic kidney disease: a look beyond the cysts","volume":"33","author":"Raptis","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0108","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0109","doi-asserted-by":"crossref","first-page":"F1012","DOI":"10.1152\/ajprenal.00181.2003","article-title":"Regulation of calcium signaling by polycystin-2","volume":"286","author":"Cantiello","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0110","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1749-6632.2010.05634.x","article-title":"Oxidative stress caused by mitochondrial calcium overload","volume":"1201","author":"Peng","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0111","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJM199010183231602","article-title":"The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease","volume":"323","author":"Chapman","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0112","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/ki.1992.413","article-title":"Renal histology in polycystic kidney disease with incipient and advanced renal failure","volume":"42","author":"Zeier","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0113","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1038\/ki.1992.297","article-title":"Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease","volume":"42","author":"Torres","year":"1992","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0114","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000354317","article-title":"A link between the intrarenal renin angiotensin system and hypertension in autosomal dominant polycystic kidney disease","volume":"38","author":"Kocyigit","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00004872-199003000-00010","article-title":"Natriuresis-pressure relationship in polycystic kidney disease","volume":"8","author":"Schmid","year":"1990","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0116","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0025-6196(12)65554-2","article-title":"Natriuretic response to volume expansion in polycystic kidney disease","volume":"64","author":"Torres","year":"1989","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0117","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3317\/jraas.2006.023","article-title":"Autosomal dominant polycystic kidney disease: role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease","volume":"7","author":"Lawson","year":"2006","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0118","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1402685","article-title":"Blood pressure in early autosomal dominant polycystic kidney disease","volume":"371","author":"Schrier","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0119","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1093\/ndt\/gfg417","article-title":"No effect of enalapril on progression in autosomal dominant polycystic kidney disease","volume":"18","author":"van Dijk","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1523-1755.2005.00077.x","article-title":"The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease","volume":"67","author":"Jafar","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0121","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010294.pub2","article-title":"Interventions for preventing the progression of autosomal dominant polycystic kidney disease","author":"Bolignano","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0122","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1093\/ndt\/gft513","article-title":"Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease","volume":"29","author":"Rahbari-Oskoui","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0123","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000013382","article-title":"Sympathetic activity and blood pressure pattern in autosomal dominant polycystic kidney disease hypertensives","volume":"18","author":"Cerasola","year":"1998","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0124","doi-asserted-by":"crossref","first-page":"H1577","DOI":"10.1152\/ajpheart.00218.2002","article-title":"Alpha(1)-adrenoceptor stimulation directly induces growth of vascular wall in vivo","volume":"283","author":"Erami","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0125","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1161\/hh2101.098379","article-title":"Trophic effect of norepinephrine on arterial intima-media and adventitia is augmented by injury and mediated by different alpha1-adrenoceptor subtypes","volume":"89","author":"Zhang","year":"2001","journal-title":"Circ Res"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0126","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1681\/ASN.V12112427","article-title":"Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension","volume":"12","author":"Klein","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0127","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1046\/j.1523-1755.2001.00936.x","article-title":"Glomerulosclerosis and progression: effect of subantihypertensive doses of alpha and beta blockers","volume":"60","author":"Amann","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2019.10.009_bib0128","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1681\/ASN.V1181469","article-title":"Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats","volume":"11","author":"Amann","year":"2000","journal-title":"J Am Soc Nephrol"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929519300944?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929519300944?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:34:37Z","timestamp":1759448077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929519300944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":128,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0270929519300944"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2019.10.009","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoxia and Endothelial Dysfunction in Autosomal-Dominant Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2019.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}